deferoxamine has been researched along with deferiprone in 397 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (2.02) | 18.7374 |
| 1990's | 67 (16.88) | 18.2507 |
| 2000's | 164 (41.31) | 29.6817 |
| 2010's | 137 (34.51) | 24.3611 |
| 2020's | 21 (5.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dobbin, PS; Hall, AD; Hider, RC; Porter, JB; Sarpong, P; Taylor, PD; van der Helm, D; Xiao, G | 1 |
| Bernhardt, PV; Islam, M; Kalinowski, DS; Lovejoy, DB; Richardson, DR; Richardson, V; Sharpe, PC | 1 |
| Bernhardt, PV; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Richardson, DR; Sharpe, PC; Siafakas, AR; Stefani, C; Yu, Y | 1 |
| Codd, R; Groebler, LK; Kalinowski, DS; Liu, J; Obando, D; Richardson, DR; Schipanski, LG; Witting, PK | 1 |
| Gehrke, SS; Hider, RC; Pinto, EG; Pleban, K; Steverding, D; Tempone, AG; Wagner, GK | 1 |
| Cohen, SM; Day, JA | 1 |
| Jiang, Z; You, Q; Zhang, X | 1 |
| Bai, R; Jiang, X; Xie, Y; Zhou, T | 1 |
| Davidoff, AM; Rankovic, Z; Wang, Y; Wu, Q; Yang, J; Young, B | 1 |
| Abdallah, MA; Brissot, P; Cillard, J; Cillard, P; Lescoat, G; Morel, I; Ocaktan, AZ; Pasdeloup, N; Sergent, O | 1 |
| Crichton, RR; Florence, A; Peters, TJ; Ward, RJ | 1 |
| al-Refaie, FN; Hoffbrand, AV; Kontoghiorghes, GJ; Wickens, DG; Wonke, B | 1 |
| Agarwal, MB; Chhablani, AT; Desai, N; Gupte, SS; Puniyani, RR; Ramanathan, J; Vasandani, D; Viswanathan, C | 1 |
| Bergeron, RJ; Creary, EA; Luchetta, G; Peter, HH; Streiff, RR; Wiegand, J | 1 |
| Kline, MA; Orvig, C | 1 |
| al-Refaie, FN; Hoffbrand, AV; Kontoghiorghes, GJ; Nortey, P; Wickens, DG; Wonke, B | 1 |
| Chandy, M | 1 |
| Campbell, RA; Gale, GR; Jones, MM; Litchenberg, WH; Singh, PK; Smith, AB | 1 |
| Bentur, Y; Chung, D; Freedman, MH; Hermann, C; Klein, J; Koren, G; McClelland, RA; Olivieri, NF; St Louis, P; Templeton, DM | 1 |
| Freedman, MH; Koren, G; McClelland, RA; Olivieri, NF; St Louis, P; Templeton, DM | 1 |
| Chung, D; Freedman, MH; Hermann, C; Koren, G; McClelland, RA; Olivieri, NF; Templeton, DM | 1 |
| Arthur, HM; Brock, JH; Kontoghiorghes, GJ; Licéaga, J | 1 |
| Barradas, MA; Dandona, P; Hoffbrand, AV; Jeremy, JY; Kontoghiorghes, GJ; Mikhailidis, DP | 1 |
| Atti, G; Borgatti, L; De Sanctis, V; Di Palma, A; Vullo, C | 1 |
| Blatt, J; Kontoghiorghes, GJ; Taylor, SR | 1 |
| Aldouri, MA; Barr, J; Hoffbrand, AV; Kontoghiorghes, GJ; Kourouclaris, T; Sheppard, L; Wonke, B | 1 |
| Dandona, P; Hoffbrand, AV; Jeremy, JY; Kontoghiorghes, GJ | 1 |
| Charalambous, J; Hoffbrand, AV; Kontoghiorghes, GJ; Pippard, MJ; Sheppard, L; Tikerpae, J | 1 |
| Kontoghiorghes, GJ | 13 |
| Buchle, AM; Steulet, AF; Waldmeier, PC | 1 |
| Olivieri, NF; Parkes, JG; Randell, EW; Templeton, DM | 1 |
| Babbs, CF; Badylak, SF; Konrad, PE; Reuter, DG; Tacker, WA; Voorhees, WD | 1 |
| Brissot, P; Cillard, J; Cillard, P; Cogrel, P; Lescoat, G; Morel, I; Pasdeloup, N; Sergent, O | 1 |
| Boelaert, J; Papavassiliou, P; Soteriadou, K; Voyiatzaki, C | 1 |
| Hileti, D; Hoffbrand, AV; Panayiotidis, P | 1 |
| Cannata-Andía, JB; Canteros, MA; Díaz-López, JB; Fernández-Martín, JL; Menéndez-Fraga, P | 1 |
| Nathan, DG | 1 |
| Corbella, J; del Castillo, D; Domingo, JL; Gómez, M; Llobet, JM | 1 |
| Halleux, C; Hamilton, KO; Hassan, I; Jin, Y; Mackay, M; Stallibrass, L | 1 |
| al-Rafaie, FN; Hoffbrand, AV; Wilkes, S; Wonke, B | 1 |
| Brabec, V; Cermák, J | 1 |
| Chablani, A; Mehta, BC; Mehta, J; Reporter, R; Singhal, S | 1 |
| Brissot, P; Gollan, J; Guyader, D; Zanninelli, G; Zeind, J | 1 |
| al-Refaie, FN; Aydinok, Y; Fielding, A; Hoffbrand, AV; Wickens, DG; Wonke, B | 1 |
| Hershko, C | 3 |
| Bentley, P; Pfannkuch, F; Schnebli, HP | 1 |
| Crowe, A; Morgan, EH | 1 |
| Hoffbrand, AV | 1 |
| Collins, AF; Fassos, FF; Fry, M; Koren, G; Lewis, N; McClelland, RA; Olivieri, NF; Shaw, D; Stobie, S; Templeton, DM | 1 |
| Hershko, C; Link, G; Pinson, A | 1 |
| al-Refaie, FN; Cunningham, JM; Hoffbrand, AV; Hunter, AE; Sheppard, LN | 1 |
| Boelaert, JR; Crichton, RR; de Locht, M; Schneider, YJ; Van Cutsem, J | 1 |
| Hider, RC; Lamb, DJ; Leake, DS | 1 |
| Kontoghiorghes, GJ; Sheppard, LN | 1 |
| Crosland, RD | 1 |
| Domingo, JL | 1 |
| Dogherty, P; Einarson, T; Koren, G; Sher, G | 1 |
| Hershko, C; Link, G; Pinson, A; Tirosh, R | 1 |
| Amankwah, K; Bradley, S; Francombe, WH; Goldberg, E; Kaufman, M; Koren, G; Olivieri, NF; Shear, N; Shilalukey, K | 1 |
| Anger, JP; Cillard, J; Cillard, P; Lescoat, G; Pasdeloup, N; Sergent, O | 1 |
| Andrews, D; Berkovitch, M; Dalal, I; Koren, G; Loebstein, R; Loubser, MD; Meydan, N; Nisbet-Brown, E; Olivieri, NF; Roifman, CM | 1 |
| Hoffbrand, AV; Wonke, B | 1 |
| Porter, JB | 3 |
| Fraser, IW; Gramacho, C; Naidoo, D; Selig, RA; Sterling-Levis, K; White, L | 1 |
| Cannata Andía, JB; Canteros, A; Elorriaga, R; Naves Díaz, ML | 1 |
| Hershko, C; Konijn, AM; Link, G | 2 |
| Brittenham, GM; Olivieri, NF | 2 |
| Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM | 1 |
| Hoffbrand, AV; Wonke, B; Wright, C | 1 |
| de Montalembert, M | 1 |
| Maggio, A; Pinzello, G; Stella, M | 1 |
| Cohen, AR; Martin, MB | 1 |
| Chiabotto, P; Di Stefano, M; Garofalo, F; Isaia, GC; Lala, R; Piga, A | 1 |
| Bartfay, WJ; Lehotay, DC; Liu, PP; Sher, GD | 1 |
| Berthon, G; Biron, F; Desroches, S | 1 |
| Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A | 1 |
| Aydinok, Y; Kavakli, K; Nisli, G | 1 |
| Aydinok, Y; Cetingül, N; Coker, C; Kantar, M; Kavakli, K; Nisli, G | 1 |
| Domingo, JL; Esparza, JL; Gómez, M; Jones, MM; Singh, PK | 1 |
| Georgiou, NA; Marx, JJ; Nottet, HS; Oudshoorn, M; van Asbeck, BS; van der Bruggen, T | 1 |
| Campisi, S; De Sanctis, V; Di Silvestro, G; Mangiagli, A; Urso, L | 1 |
| Blanusa, M; Jones, MM; Kostial, K; Pavlović, D; Prester, L; Singh, PK; Varnai, VM | 1 |
| del Castillo, D; Domingo, JL; Esparza, JL; Gómez, M; Hernández, M | 1 |
| Anderson, D; Chua-Anusorn, W; Cole, C; Vives-Bauza, C; Webb, J; Yardley-Jones, A | 1 |
| Pippard, MJ; Weatherall, DJ | 1 |
| Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K | 1 |
| De Luca, C; Deeva, I; Korkina, L; Nobili, B; Passi, S; Perrotta, S; Puddu, P | 1 |
| Abramov, A; Breuer, W; Cabantchik, ZI; Ermers, MJ; Hershko, C; Pootrakul, P | 1 |
| Cook, J | 1 |
| Balveer, K; Pyar, K; Wonke, B | 1 |
| Richardson, DR | 2 |
| Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R | 1 |
| Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Inati, A; Koussa, S; Mourad, F; Neeman, R; Sheikh-Taha, M; Taher, A | 1 |
| Cambier, N; Ernst, O; Fenaux, P; Mahieu, M; Rose, C | 1 |
| Cleveland, JL; Maclean, KH; Porter, JB | 1 |
| Eybl, V; Kolek, M; Kotyzová, D; Koutenský, J; Nielsen, P | 1 |
| Hershko, C; Huerta, M; Konijn, AM; Link, G; Reinus, C; Rosenmann, E | 1 |
| Andrei, G; Boelaert, JR; De Clercq, E; Mosselmans, R; Noel, JC; Simonart, T; Snoeck, R | 1 |
| Carniel, E; Foulon, J; Lesic, B | 1 |
| Anderson, LJ; Holden, S; Pennell, DJ; Prescott, E; Walker, JM; Wonke, B | 1 |
| Badakere, S; Ghosh, K; Pradhan, V | 1 |
| St Pierre, TG | 1 |
| Engelhardt, R; Fischer, R | 1 |
| Brittenham, GM; Nathan, DG; Olivieri, NF; Pippard, MJ; Weatherall, DJ | 1 |
| Kolnagou, A; Kontoghiorghes, GJ | 8 |
| Hoffbrand, VA; Wonke, B | 1 |
| Gordeuk, VR; Loyevsky, M | 1 |
| Hoffbrand, AV; Khoriaty, AI; Koussa, S; Mourad, FH; Sheikh-Taha, M; Taher, A | 1 |
| Baker, E; Chua, AC; Ingram, HA; Raymond, KN | 1 |
| Anderson, LJ; Pennell, DJ; Westwood, M | 1 |
| Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F | 1 |
| Chen, JH; Chiang, YP; Chow, KC; Lin, TY; Peng, CT; Tsai, CH | 1 |
| Cannata Andía, JB; Fernández Martín, JL; González Suárez, I; Naves Díaz, M | 1 |
| Bartolotta, V; Borsellino, Z; Capra, M; D'Ascola, DG; Galia, M; Gerardi, C; Maggio, A; Magnano, C; Malizia, R; Mangiagli, A; Midiri, M; Morabito, A; Rigano, P; Rizzo, M | 1 |
| Engelhardt, R; Fischer, R; Hider, RC; Longo, F; Nielsen, P; Piga, A | 1 |
| Andrei, G; Boelaert, JR; Clercq, ED; Simonart, T; Snoeck, R | 1 |
| Galanello, R; Kirkland, D; Leoni, G; Marshall, R; Minto, S; Spino, M; Tricta, F | 1 |
| Weinberg, ED | 1 |
| Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M | 1 |
| Chang, JS; Peng, CT; Tsai, CH; Wu, KH | 1 |
| Athanassiou-Metaxa, M; Economou, M; Kanakoudi-Tsakalidou, F; Taparkou, A; Tourkantoni, N; Tzimouli, V | 1 |
| Berdousi, H; Kassou, C; Kattamis, A; Kattamis, C; Ladis, V; Papassotiriou, I | 1 |
| Chiabotto, P; Di Stefano, M; Garofalo, F; Isaia, GC; Lala, R; Piga, A; Roggia, C | 1 |
| Simonart, T | 1 |
| Gomber, S; Madan, N; Saxena, R | 1 |
| D'Amico, G; Maggio, A; Morabito, A | 1 |
| Athanassiou-Metaxa, M; Hatzipantelis, ES; Ikonomou, M; Kousi, A; Perifanis, V; Tsantali, H; Tsatra, I | 1 |
| Arosio, C; Grisoli, M; Mariani, R; Pelucchi, S; Piga, A; Piperno, A; Trombini, P | 1 |
| Cappellini, MD; Galanello, R; Hershko, C; Masera, G; Piga, A; Tognoni, G | 1 |
| Alymara, V; Bouranta, P; Bourantas, D; Bourantas, KL; Chaidos, A; Gouva, M; Tzouvara, E; Vassou, A | 1 |
| Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Meletis, J; Tsironi, M | 1 |
| Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
| Cabantchik, ZI; El, RB; Glickstein, H; Shvartsman, M | 1 |
| Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M | 1 |
| Loukopoulos, D | 1 |
| Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R | 1 |
| Alderson, P; Brunskill, S; Howard, J; Hyde, C; Rees, D; Roberts, DJ | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 3 |
| Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Gallo, V; Longo, F; Piga, A; Roggero, S; Sacchetti, L; Vinciguerra, T | 1 |
| Kattamis, A | 1 |
| Fischer, R; Harmatz, P; Nielsen, P; Piga, A | 1 |
| Pennell, DJ | 1 |
| Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B | 1 |
| Borgna-Pignatti, C; Cappellini, MD; Cnaan, A; De Stefano, P; Del Vecchio, GC; Forni, GL; Gamberini, MR; Ghilardi, R; Piga, A; Romeo, MA; Zhao, H | 1 |
| Greenberg, PL | 1 |
| Estornell, J; Martín, M; Martínez, V; Orero, M; Pérez, JL; Ridocci, F | 1 |
| Daar, S; Pathare, AV | 1 |
| Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L | 1 |
| Anagnostopoulos, G; Farmaki, K; Gotsis, E; Platis, O; Posantzis, M; Tolis, G | 1 |
| Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP | 1 |
| Duca, L; La Rosa, MA; Meo, A; Morabito, N; Ruggeri, A; Zanghì, L | 1 |
| Neufeld, EJ | 1 |
| Cirò, A; Masera, G; Masera, N; Russo, P; Tavecchia, L; Vimercati, C; Vincenzi, A | 1 |
| Peng, CT; Tsai, CH; Wu, KH; Wu, SF | 1 |
| Chang, JS; Huang, YC; Peng, CT; Wu, KH | 1 |
| Chang, JG; Ho, YJ; Peng, CT; Wu, KH; Wu, SF | 1 |
| Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH | 1 |
| Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO | 1 |
| Mudiyanse, RM | 1 |
| Kuo, HT; Peng, CT; Tsai, MY; Wu, KH | 1 |
| Kuo, HT; Peng, CT; Tsai, MY | 1 |
| Anagnostopoulos, G; Angelopoulos, N; Farmaki, K; Gotsis, E; Rombopoulos, G; Tolis, G | 1 |
| El Kelany, RS; Emara, AM; Moustafa, KA | 1 |
| Amiri, A; Fatemi, SJ; Fatemi, SN | 1 |
| Athanassiou-Metaxa, M; Christoforidis, A; Perifanis, V; Tsatra, I; Vlachaki, E | 1 |
| Angastiniotis, M; Christou, S; Coen, PG; Hadjigavriel, M; Kolnakou, A; Pangalou, E; Pavlides, N; Psiloines, M; Simamonian, K; Sitarou, M; Skordos, G; Telfer, P | 1 |
| Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V | 1 |
| Bianchi, A; Cappellini, MD; Delbini, P; Fabio, G; Minonzio, F | 1 |
| Corda, M; Galanello, R; Landis, N; Matta, G; Orrù, P; Porcu, M; Salis, S; Serra, E; Usai, B | 1 |
| Athanassiou-Metaxa, M; Christoforidis, A; Haritandi, A; Karyda, S; Tsatra, I; Tsitourides, I | 1 |
| Athanassiou-Metaxa, M; Haralambidou-Vranitsa, S; Ioannidou-Papagiannaki, E; Klonizakis, I; Perifanis, V; Tziomalos, K; Vlachaki, E | 1 |
| Dewan, P; Gomber, S | 1 |
| De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C | 1 |
| Barton, JC | 1 |
| Agus, A; Assomull, R; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Roughton, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA | 1 |
| Brunskill, SJ; Doree, C; Howard, J; Hyde, CJ; Roberts, DJ; Williams, S | 1 |
| Maggio, A | 1 |
| Apostolakou, F; Athanassiou-Metaxa, M; Christoforidis, A; Papassotiriou, I; Perifanis, V; Tsatra, I; Vlachaki, E; Zevgaridou, E | 1 |
| Abdelrazik, N | 1 |
| Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK | 1 |
| Bernhardt, PV | 1 |
| Fucharoen, S; Phisalaphong, C; Porter, JB; Srichairatanakool, S; Thephinlap, C | 1 |
| Amer, J; Fibach, E; Ghoti, H; Rachmilewitz, E; Winder, A | 1 |
| Aessopos, A; Deftereos, S; Farmakis, D; Kati, M; Polonifi, E; Tsironi, M | 1 |
| Aydinok, Y; Cetiner, N; Ellis, G; Manz, C; Nart, D; Terzi, A; Ulger, Z; Zimmermann, A | 1 |
| Athanassiou-Metaxa, M; Christoforidis, A; Perifanis, V; Spanos, G; Tsatra, I; Vlachaki, E | 1 |
| Berdoukas, V; Modell, B | 1 |
| Francis, S; Kidson-Gerber, GL; Lindeman, R | 1 |
| Dimanche-Boitrel, MT; Fardel, O; Gorria, M; Holme, JA; Huc, L; Lagadic-Gossmann, D; Landvik, N; Rissel, M; Sergent, O; Tekpli, X | 1 |
| Kolnagou, A; Kontoghiorghes, GJ; Kontos, C; Kyriacou, K; Michaelides, Y | 1 |
| Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M | 1 |
| Athanassiou-Metaxa, M; Economou, M; Kanakoudi-Tsakalidou, F; Perifanis, V; Taparkou, A; Tourkantoni, N; Tzimouli, V; Zafiriou, D | 1 |
| Peng, CT; Tsai, CH; Wu, KH | 1 |
| Bring, P; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA | 1 |
| El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I | 1 |
| Kwiatkowski, JL | 2 |
| Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S | 1 |
| Kidson-Gerber, G; Lindeman, R | 1 |
| Aguilar, M; Moats, R; Nelson, MD; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Abetz, L; Baladi, JF; Desrosiers, MP; Ishak, K; Lordan, N; Payne, KA; Proskorovsky, I; Rofail, D; Viala, M | 1 |
| Edwards, J; Ibrahim, AS; Spellberg, B | 1 |
| Fatemi, SJ; Tubafard, S | 1 |
| Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP | 1 |
| Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
| Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A | 1 |
| Argento, C; Campisi, S; Capra, M; Caruso, V; Cianciulli, P; Cuccia, L; D'Amico, G; D'Ascola, DG; Fidone, C; Filosa, A; Gagliardotto, F; Gerardi, C; Gluud, C; Maggio, A; Magnano, C; Malizia, R; Morabito, A; Pepe, A; Prossomariti, L; Quota, A; Rigano, P; Rizzo, M; Romeo, MA; Violi, P; Vitrano, A | 1 |
| Kim, CM; Shin, SH | 1 |
| Kim, DM; Neupane, GP | 1 |
| Berdoukas, V; Berdoussi, E; Chouliaras, G; Ladis, V; Moraitis, P; Zannikos, K | 1 |
| Cappellini, MD; Pattoneri, P | 1 |
| Cohan, N; Haghpanah, S; Jabbari, A; Zareifar, S | 1 |
| Breuer, W; Cabantchik, ZI; Zanninelli, G | 1 |
| Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ; Yazman, D | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Chu, WC; Ha, SY; Ho, MH; Mok, AS; Raskalkar, DD | 1 |
| Chan, GC; Chan, S; Ha, SY; Ho, PL | 1 |
| Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y | 1 |
| Angastiniotis, M; Christou, S; Hadjigavriel, M; Kolnagou, A; Sitarou, M; Telfer, PT; Warburton, F | 1 |
| Fabron, A; Fernandes, JL; Verissimo, M | 1 |
| Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I | 1 |
| Fibach, E; Prus, E | 1 |
| Cappellini, MD; Musallam, KM; Taher, AT | 1 |
| Telfer, P | 1 |
| Drakonaki, EE; Karantanas, AH; Klironomos, V; Maragaki, S; Maris, TG; Papadakis, A | 1 |
| Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V | 1 |
| Berdoukas, V; Carson, S; Coates, T; Dongelyan, A; Gavin, S; Hofstra, TC; Nord, A; Wood, JC | 1 |
| Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Fausel, CA | 1 |
| Balocco, M; Carrara, P; Forni, GL; Pinto, V | 1 |
| Farmaki, K; Fragatou, S; Kremastinos, D; Kyrzopoulos, S; Paraskevaidis, I; Tsiapras, D; Voudris, V | 1 |
| Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A | 1 |
| Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K | 1 |
| Gailer, J; Sooriyaarachchi, M | 1 |
| Waalen, J | 1 |
| Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB | 1 |
| Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ | 3 |
| Bina, P; Carta, MP; Cianciulli, P; Farci, P; Galanello, R; Grady, RW; Lai, ME; Maggio, A; Pepe, A; Sau, F; Vacquer, S | 1 |
| Longo, F; Massano, D; Piga, A; Roggero, S; Salussolia, I; Serra, M | 1 |
| Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW | 1 |
| Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
| Ward, R | 1 |
| Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G | 1 |
| Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Porter, JB; Shah, FT | 1 |
| Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS | 1 |
| Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C | 1 |
| Naftalin, RJ; Sharp, PA; Vlachodimitropoulou, E | 1 |
| Mullié, C; Sonnet, P | 1 |
| Berdoukas, V; Coates, T; Farmaki, K; Wood, JC | 1 |
| Chao, NJ; Kanda, J; Kawabata, H | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Chu, WC; Ha, SY; Ho, MH; Mok, AS; Rasalkar, DD | 1 |
| Argento, C; Campisi, S; Capra, M; Caruso, V; Cianciulli, P; Cuccia, L; D'Amico, G; D'Ascola, DG; Fidone, C; Filosa, A; Gagliardotto, F; Gerardi, C; Gluud, C; Maggio, A; Magnano, C; Malizia, R; Morabito, A; Pantalone, GR; Pepe, A; Prossomariti, L; Quota, A; Rigano, P; Rizzo, M; Romeo, MA; Violi, P; Vitrano, A | 1 |
| Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P | 1 |
| Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA | 1 |
| Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J | 1 |
| El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
| Aydinok, Y; Evans, P; Manz, CY; Porter, JB | 1 |
| Alpendurada, F; Banya, W; Carpenter, JP; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Smith, GC; Tanner, MA; Walker, JM | 1 |
| Pankaew, T; Torcharus, K | 1 |
| Fernandes, JL | 1 |
| Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E | 1 |
| Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ | 1 |
| Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L | 1 |
| Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Di Maggio, R; Filosa, A; Gagliardotto, F; Gerardi, C; Lucania, G; Maggio, A; Pantalone, GR; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A | 1 |
| Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
| Jahazi, A; Mirbehbahani, N; Rahim Abad, HH | 1 |
| Corey, BW; Craft, DW; Si, Y; Thompson, MG; Zurawski, DV | 1 |
| Kummel, AC; Liberman, A; Pohaku Mitchell, KK; Trogler, WC | 1 |
| Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
| Ioannou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Natsiopoulos, K | 1 |
| Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H | 1 |
| Ruivard, M | 1 |
| Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A | 1 |
| Kurtoglu, E; Uygun, V | 1 |
| Campisi, S; Caruso, V; Cianciulli, P; Cuccia, L; D'Ascola, GD; Filosa, A; Gulino, L; Lombardi, M; Meloni, A; Midiri, M; Missere, M; Peluso, A; Pepe, A; Pitrolo, L; Positano, V; Putti, MC; Ricchi, P; Romeo, MA; Rossi, G; Santodirocco, M | 1 |
| Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G | 1 |
| Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A | 1 |
| Evans, P; Giardina, P; Kim, HY; Macklin, EA; Moore, B; Neufeld, E; Olivieri, N; Porter, JB; Taher, A; Thompson, A; Trachtenberg, F; Vichinsky, EP; Wood, J | 1 |
| Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C | 1 |
| Chao, YH; Lin, CD; Lin, CY; Peng, CT; Tsai, MH; Wu, HP; Wu, KH | 1 |
| Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ | 2 |
| Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R | 1 |
| Khatiwada, CP; Raja, B; Sivakumar, S; Sivasubramanian, J | 2 |
| Economou, M; Hatzipantelis, ES; Karasmanis, K; Perifanis, V; Tziomalos, K; Vlachaki, E | 1 |
| Qiao, C; Wang, L; Xiao, SH; Xue, J | 1 |
| Huang, L; Jiang, H; Xia, S; Zhang, W | 1 |
| LeVine, SM; Lynch, SG; Weigel, KJ | 1 |
| Aburjai, TA; Alkhalil, SM; Ikeda, R; Komatsu, H; Kuroda, N; Nakashima, K; Wada, M | 1 |
| Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA | 1 |
| Khatiwada, CP; Sivakumar, S; Sivasubramanian, J | 2 |
| Merkel, DG; Nagler, A | 1 |
| Ballas, S; Barone, R; Calvaruso, G; Di Maggio, R; Maggio, A; Renda, D; Rigano, P; Sacco, M; Steinberg, MH; Telfer, P; Vitrano, A | 1 |
| Chaisri, U; Fucharoen, S; Hemstapat, W; Morales, NP; Srichairatanakool, S; Svasti, S; Wichaiyo, S; Yatmark, P | 3 |
| Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY | 1 |
| Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V | 1 |
| Kuo, KH; Mrkobrada, M | 1 |
| Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Sungkarat, W; Wongwerawattanakoon, P | 1 |
| Aaseth, J; Andersen, O; Cao, Y; Skaug, MA | 1 |
| Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z | 1 |
| Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y | 1 |
| Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A | 1 |
| Badat, M; Kaya, B; Telfer, P | 1 |
| Bina, P; Civolani, A; Cunico, A; Danjou, F; Defraia, E; Dessì, C; Follesa, I; Foschini, ML; Leoni, G; Moi, P; Morittu, M; Origa, R; Podda, RA; Zappu, A | 1 |
| Garbowski, M; Porter, J; Vlachodimitropoulou Koumoutsea, E | 1 |
| Alberti, G; Biesuz, R; Crespo-Alonso, M; Crisponi, G; Nurchi, VM; Sanna, G; Zoroddu, MA | 1 |
| Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA | 1 |
| Chen, V; Clemons, KV; Cohen, K; Ferreira, JA; Haagensen, JA; Hsu, JL; Martinez, M; Nazik, H; Penner, JC; Spormann, AM; Stevens, DA | 1 |
| Masri, C; Nijjar, PS; Tamene, A; Valeti, U; Vongooru, H | 1 |
| El Rassi, F; Saliba, AN; Taher, AT | 1 |
| Aguirre, P; Carrasco, CM; Cassels, BK; García-Beltrán, O; González-Billault, C; Mena, NP; Méndez-Gálvez, C; Morales, RA; Muñoz, Y; Núñez, MT; Pérez-Henríquez, P | 1 |
| Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E | 1 |
| Baiardi, P; Bartoloni, F; Bonifazi, D; Bonifazi, F; Ceci, A; Conte, R; Del Vecchio, GC; Felisi, M; Filosa, A; Gambino, A; Giannuzzi, V; Iacono, A; Maggio, A; Mangiarini, L; Padula, R; Pepe, A; Putti, MC; Ruggieri, L | 1 |
| Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Chiou, SS; Kou, HS; Lin, HJ; Wu, SM | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Fraňková, S; Jirsa, M; Kautzner, J; Kautznerová, D; Křížová, B; Kubánek, M; Malušková, J; Melenovský, V; Tauchenová, L; Tintěra, J | 1 |
| Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A | 1 |
| Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S | 1 |
| Kolnagou, A; Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
| Hadjidemetriou, M | 1 |
| Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Leitch, HA; Wong, SA | 1 |
| Elgharabawy, RM; Elgharbawy, DM; Emara, AM | 1 |
| Bagmar, S; Dabas, A; Gomber, S; Madhu, SV | 1 |
| Aminasnafi, A; Mirlohi, MS; Olapour, S; Shirali, S; Yaghooti, H | 1 |
| Ballas, SK; DeVeaux, M; Duong, VH; Heeney, MM; Zeidan, AM | 1 |
| Crumbliss, AL; Harrington, JM; Mysore, MM | 1 |
| Sivaramakrishnan, G; Sridharan, K | 1 |
| Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
| Allan, DS; Davidson, RJ; Fidel, PL; Holbein, BE; Lilly, EA; Parquet, MC; Savage, KA | 1 |
| Lee, JA; Tchantchaleishvili, V; Vidula, H | 1 |
| Sari, TT; Wahidiyat, PA; Yosia, M | 1 |
| Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A | 1 |
| Hider, RC; Hoffbrand, AV | 1 |
| Ghosh, K | 1 |
| Bagheri, B; Eghbali, A; Khalilpour, A; Taherahmadi, H | 1 |
| Chen, X; Hsieh, YW; Lin, CH; Peng, CT; Song, TS; Weng, TF; Wu, CC; Wu, KH | 1 |
| Allò, M; Borsellino, Z; Casale, M; Casini, T; D'Ascola, DG; Fidone, C; Filosa, A; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Midiri, M; Pepe, A; Pistoia, L; Positano, V; Putti, MC; Quarta, A; Restaino, G | 1 |
| Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG | 1 |
| Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH | 1 |
| Brett, E; Bukowiecki, J; Duscher, D; Pförringer, D; Thor, D | 1 |
| Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ | 1 |
| Barati, M; Iranshahy, M; Moinipour, N; Sahebkar, A; Shakeri, A | 1 |
| Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S | 1 |
| Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S | 1 |
| Applová, L; Franz, KJ; Hašková, P; Homola, P; Jansová, H; Roh, J; Šimůnek, T; Vávrová, K | 1 |
| Argenziano, M; Di Paola, A; Marrapodi, MM; Rossi, F; Tortora, C | 1 |
| Feng, W; Ganz, T; Liu, S; Liu, W; Ma, J; Xiao, Y; Zhang, J; Zhang, Z; Zhao, C | 1 |
| Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
| Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y | 1 |
| Aydinok, Y | 1 |
| Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S | 1 |
| Aessopos, A; Berdoukas, V; Drakaki, K; Fragodimitri, C; Giakoumis, A; Karageorga, M; Karampatsos, F; Salichou, A; Schiza, V; Yousef, J | 1 |
81 review(s) available for deferoxamine and deferiprone
| Article | Year |
|---|---|
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Topics: Animals; Antineoplastic Agents; Humans; Iron; Iron Chelating Agents; Ribonucleotide Reductases; Thiosemicarbazones | 2009 |
Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective.
Topics: Animals; Catalytic Domain; Chelating Agents; Chemistry, Pharmaceutical; Drug Design; Humans; Metalloproteins | 2019 |
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.
Topics: Animals; Humans; Iron Chelating Agents; Iron Overload; Pyridones | 2020 |
Recent Advances with KDM4 Inhibitors and Potential Applications.
Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neoplasms | 2022 |
[Iron-chelating treatment].
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Erythropoiesis; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Pentetic Acid; Pyridones; Thalassemia | 1989 |
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Topics: Administration, Oral; Aluminum; Animals; Chelating Agents; Clinical Protocols; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones | 1995 |
Prospects for oral iron chelation therapy.
Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones | 1994 |
Adverse effects of aluminium-chelating compounds for clinical use.
Topics: Aluminum; Animals; Antidotes; Chelating Agents; Deferiprone; Deferoxamine; Humans; Pyridones | 1996 |
Iron chelation therapy.
Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones | 1997 |
A risk-benefit assessment of iron-chelation therapy.
Topics: Administration, Oral; Clinical Trials as Topic; Deferiprone; Deferoxamine; Guidelines as Topic; Humans; Infusions, Parenteral; Injections, Subcutaneous; Iron; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Risk Assessment | 1997 |
Iron chelators for thalassaemia.
Topics: Administration, Oral; Aza Compounds; Chelating Agents; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron; Iron Chelating Agents; Iron Overload; Long-Term Care; Pyridones; Thalassemia | 1998 |
Long-term trials of deferiprone in Cooley's anemia.
Topics: beta-Thalassemia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Pyridones | 1998 |
[Iron chelation in 1998].
Topics: Administration, Oral; Deferiprone; Deferoxamine; Ferritins; Humans; Injections, Intramuscular; Injections, Subcutaneous; Iron; Iron Chelating Agents; Iron Overload; Pyridones | 1998 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Pyridones; Transfusion Reaction | 2000 |
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction | 2000 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Liver Cirrhosis; Neutropenia; Pyridones; Thalassemia; Treatment Outcome | 2001 |
[Iron overload and myelodysplastic syndromes].
Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Prognosis; Pyridones; Risk; Sensitivity and Specificity; Severity of Illness Index | 2001 |
Long term deferiprone chelation therapy.
Topics: Animals; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Time Factors | 2002 |
Antimalarial effect of iron chelators.
Topics: Animals; Antimalarials; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Malaria; Malaria, Cerebral; Malaria, Falciparum; Plasmodium falciparum; Pyridones | 2002 |
Iron chelation in chemotherapy.
Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Lactoferrin; Pyridones; Transferrin | 2003 |
Pharmacotherapy of iron overload in thalassaemic patients.
Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Transfusion Reaction; Treatment Outcome | 2003 |
Purging iron from the heart.
Topics: Cardiomyopathies; Cardiotonic Agents; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Pyridones | 2004 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles | 2005 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Transfusion Reaction | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up Studies; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Liver; Liver Cirrhosis; Neutropenia; Pyridones; Retrospective Studies; Thalassemia | 2005 |
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Thalassemia; Treatment Outcome | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles | 2005 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myocardium; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Reproducibility of Results; Stroke Volume; Thalassemia; Transfusion Reaction; Treatment Outcome | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Treatment Outcome | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Middle Aged; Patient Compliance; Pyridones; Thalassemia; Transfusion Reaction; Treatment Refusal | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles | 2007 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2008 |
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Taiwan; Thalassemia | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles | 2008 |
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles | 2008 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2009 |
Overview of iron chelation therapy with desferrioxamine and deferiprone.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Pyridones; Treatment Outcome | 2009 |
Update on survival in thalassemia major.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles | 2009 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles | 2010 |
An update on disordered iron metabolism and iron overload.
Topics: Animals; Blood Transfusion; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2010 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles | 2011 |
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function | 2011 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles | 2013 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Administration, Oral; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Treatment Outcome | 2013 |
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles | 2013 |
Iron chelation and multiple sclerosis.
Topics: Animals; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Multiple Sclerosis; Pyridones | 2014 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones | 2014 |
Chelation in metal intoxication--Principles and paradigms.
Topics: Administration, Oral; Antidotes; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Heavy Metal Poisoning; Humans; Penicillamine; Poisoning; Pyridones; Succimer; Triazoles; Trientine; Unithiol | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles | 2016 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2017 |
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Medication Adherence; Survival Analysis | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles | 2018 |
The Role of Deferiprone in Iron Chelation.
Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Thalassemia | 2018 |
Protective Effects of Curcumin against Iron-induced Toxicity.
Topics: Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones | 2022 |
Emerging Roles of the Iron Chelators in Inflammation.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agents; Iron Overload; Mammals; Pyridones | 2022 |
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Clinical Challenges with Iron Chelation in Beta Thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles | 2023 |
62 trial(s) available for deferoxamine and deferiprone
| Article | Year |
|---|---|
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Joints; Pain; Pyridones; Time Factors | 1992 |
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
Topics: Adult; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Male; Neutropenia; Pyridones; Thalassemia | 1992 |
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Blood Transfusion; Child; Cohort Studies; Combined Modality Therapy; Deferiprone; Deferoxamine; Diet; Dogs; Drug Administration Schedule; Drug Overdose; Erythrocyte Transfusion; Feces; Humans; Infusions, Parenteral; Intestinal Absorption; Iron; Middle Aged; Patient Compliance; Pilot Projects; Pyridones; Thalassemia | 1990 |
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Humans; Iron; Iron Chelating Agents; Pilot Projects; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Transfusion Reaction | 1990 |
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Topics: Administration, Oral; Adult; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Thalassemia; Transfusion Reaction | 1990 |
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ascorbic Acid; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Neural Tube Defects; Pyridones; Thalassemia | 1987 |
Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
Topics: Adolescent; Adult; Antibody Formation; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Humans; Immunity, Cellular; Iron Chelating Agents; Pyridones | 1997 |
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Liver Cirrhosis; Logistic Models; Male; Pyridones; Treatment Failure | 1998 |
Combined therapy with deferiprone and desferrioxamine.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pyridones; Thalassemia; Transfusion Reaction | 1998 |
Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.
Topics: Adolescent; Adult; Arthralgia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Hepatitis C Antibodies; Humans; Iron; Iron Chelating Agents; Male; Nausea; Pyridones; Thalassemia; Treatment Outcome; Treatment Refusal | 1999 |
Combined oral and parenteral iron chelation in beta thalassaemia major.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Liver; Male; Pyridones | 2000 |
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Growth Disorders; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Iron Overload; Male; Nervous System Diseases; Pain; Patient Compliance; Pyridones; Safety; Tachycardia; Transfusion Reaction; Treatment Outcome; Zinc | 2001 |
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Overload; Male; Pyridones; Statistics, Nonparametric | 2003 |
Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver Function Tests; Magnetic Resonance Imaging; Male; Myocardium; Pyridones; Stroke Volume; Taiwan | 2003 |
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
Topics: Administration, Oral; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Function Tests; Humans; Infusions, Parenteral; Iron; Iron Chelating Agents; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Pyridones | 2003 |
Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Topics: Adolescent; Adult; beta-Thalassemia; Cell Cycle; Chelation Therapy; Chromosome Aberrations; Cross-Over Studies; Deferiprone; Deferoxamine; Female; Humans; In Situ Hybridization, Fluorescence; Iron Chelating Agents; Male; Mutagens; Pyridones | 2003 |
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Splenectomy; Tissue Distribution; Transfusion Reaction; Treatment Outcome | 2003 |
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs.
Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Body Weights and Measures; Bone and Bones; Bone Density; Child; Deferiprone; Deferoxamine; Female; Femur; Ferritins; Humans; Iron Chelating Agents; Lumbar Vertebrae; Male; Prospective Studies; Pyridones; Thalassemia; Time Factors | 2004 |
Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
Topics: Blood Transfusion; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Pyridones; Thalassemia | 2004 |
Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Homozygote; Humans; Iron Overload; Pyridones | 2004 |
Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Ferritins; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Male; Middle Aged; Pyridones; Treatment Outcome | 2004 |
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Male; Pyridones; Siderosis | 2006 |
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Remission Induction; Siderophores; Time Factors | 2006 |
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Humans; Iron Overload; Magnetic Resonance Imaging; Magnetics; Male; Middle Aged; Myocardium; Pyridones | 2006 |
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Ferritins; Glucose Intolerance; Glucose Tolerance Test; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones | 2004 |
Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
Topics: Adolescent; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Male; Pyridones; Taiwan; Treatment Outcome | 2006 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Ferritins; Heart Failure; Hemosiderosis; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Iron; Iron Chelating Agents; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Pyridones; Transfusion Reaction | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modality Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Dwarfism, Pituitary; Endocrine System Diseases; Female; Human Growth Hormone; Humans; Hypogonadism; Infusions, Parenteral; Iron Chelating Agents; Iron Overload; Male; Patient Compliance; Puberty, Delayed; Pyridones; Subcutaneous Tissue; Transfusion Reaction | 2006 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined Modality Therapy; Deferiprone; Deferoxamine; Drug Eruptions; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hong Kong; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Transfusion Reaction | 2006 |
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
Topics: Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overload; Male; Pyridones; Thalassemia; Treatment Outcome | 2006 |
Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Pyridones; Sensitivity and Specificity; Treatment Outcome | 2007 |
Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Male; Neutropenia; Pyridones; Reference Values; Treatment Outcome | 2007 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Ferritins; Gastrointestinal Diseases; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Spectroscopy; Male; Myocardium; Neutropenia; Pyridones; Stroke Volume | 2007 |
Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Ferritins; Heart Function Tests; Humans; Iron; Iron Chelating Agents; Pyridones | 2007 |
A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Liver; Male; Pyridones; Siderophores; Time Factors | 2007 |
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Italy; Liver; Magnetic Resonance Imaging; Male; Myocardium; Natriuretic Peptide, Brain; Prospective Studies; Pyridones; Severity of Illness Index; Siderosis; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Patient Compliance; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction | 2008 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult | 2009 |
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Follow-Up Studies; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Pyridones; Thalassemia; Treatment Outcome; Young Adult | 2009 |
Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; beta-Thalassemia; Blood Urea Nitrogen; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Pyridones | 2009 |
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Endocrine System Diseases; Female; Ferritins; Follow-Up Studies; Humans; Hypothyroidism; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Thyroxine; Transfusion Reaction; Young Adult | 2010 |
Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
Topics: beta-Thalassemia; Bone Marrow; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Liver; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Spleen | 2010 |
Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Siderophores; Young Adult | 2010 |
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Topics: Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pyridones; Siderophores; Thalassemia; Treatment Outcome | 2010 |
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Longitudinal Studies; Magnetic Resonance Imaging; Myocardium; Pyridones | 2011 |
Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Heart Diseases; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Myocardium; Patient Selection; Pyridones; Risk Assessment; Stroke Volume; Young Adult | 2011 |
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Young Adult | 2011 |
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Topics: Adolescent; beta-Thalassemia; Blood Proteins; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Longitudinal Studies; Protein Binding; Pyridones; Young Adult | 2012 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult | 2012 |
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Ventricles; Humans; Iron Chelating Agents; Male; Models, Biological; Pyridones; Retrospective Studies; Stroke Volume; Time Factors; Ultrasonography | 2012 |
The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Male; Pyridones | 2012 |
The effects of chelators on zinc levels in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc | 2013 |
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Lebanon; Male; Ontario; Prospective Studies; Pyridones; Recovery of Function; Siderophores; Stroke Volume; Time Factors; Treatment Outcome; United States; Ventricular Function, Left; Young Adult | 2013 |
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Linear Models; Male; Middle Aged; Pyridones; Survival Analysis | 2014 |
Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; beta-Thalassemia; Child; Child, Preschool; Creatinine; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Hemoglobin E; Humans; Infusions, Subcutaneous; Male; Neutropenia; Pyridones; Siderophores; Thrombocytopenia | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles | 2015 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Linear Models; Male; Middle Aged; Neutropenia; Pyridones; Survival Analysis; Transfusion Reaction | 2015 |
Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iran; Iron Chelating Agents; Liver; Male; Middle Aged; Myocardium; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Time Factors; Young Adult | 2019 |
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Topics: Administration, Oral; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pilot Projects; Young Adult | 2019 |
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Thalassemia; Transferases | 2022 |
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Topics: Anemia; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2023 |
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Neutropenia; Pyridones | 2024 |
254 other study(ies) available for deferoxamine and deferiprone
| Article | Year |
|---|---|
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
Topics: Administration, Oral; Animals; Crystallography; Deferoxamine; Horses; Humans; Iron; Iron Chelating Agents; Liver; Mice; Pyridones; Rats; Stereoisomerism; Structure-Activity Relationship | 1993 |
2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
Topics: Antineoplastic Agents; Ascorbic Acid; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Electrochemical Techniques; Humans; Iron; Iron Chelating Agents; Oxidation-Reduction; Pyridines; Stereoisomerism; Structure-Activity Relationship; Thiosemicarbazones; Transferrin | 2009 |
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Chelating Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deferoxamine; Dogs; Ferric Compounds; Humans; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Iron Overload; Kidney; Models, Molecular; Molecular Structure; Neuroectodermal Tumors, Primitive, Peripheral; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Transferrin | 2010 |
Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators.
Topics: Aminoquinolines; Antiprotozoal Agents; Deferiprone; Dose-Response Relationship, Drug; Iron Chelating Agents; Leishmania infantum; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Trypanosoma brucei brucei; Trypanosoma cruzi | 2013 |
Investigating the selectivity of metalloenzyme inhibitors.
Topics: Biocatalysis; Carbonic Anhydrase II; Enzyme Assays; Enzyme Inhibitors; Enzymes; Histone Deacetylase 2; Humans; Hydroxamic Acids; Kinetics; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Metalloproteins; Molecular Structure; Monophenol Monooxygenase; Peptidyl-Dipeptidase A | 2013 |
Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Topics: Animals; Antioxidants; Calcium-Binding Proteins; Cells, Cultured; Chromatography, High Pressure Liquid; Cyclic N-Oxides; Deferiprone; Deferoxamine; Ethanol; Free Radical Scavengers; Free Radicals; Hydroxides; Hydroxyl Radical; Iron; Iron Chelating Agents; Kinetics; Lipid Peroxidation; Liver; Malondialdehyde; Oligopeptides; Photolysis; Pigments, Biological; Pyridones; Rats; Rats, Sprague-Dawley | 1992 |
Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Topics: Animals; Brain; Deferiprone; Deferoxamine; Disease Models, Animal; Ferrous Compounds; Heart; Hemochromatosis; Iron; Iron Chelating Agents; Liver; Male; Metallocenes; Organometallic Compounds; Pyridones; Rats; Rats, Wistar; Spleen; Subcellular Fractions | 1992 |
Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Patient Compliance; Pyridones; Transferrin | 1992 |
A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Topics: Animals; Bile; Cebus; Deferiprone; Deferoxamine; Feces; Iron; Iron Chelating Agents; Kinetics; Male; Pyridones; Rats; Rats, Inbred Strains | 1992 |
Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone).
Topics: Chelating Agents; Computer Simulation; Deferiprone; Deferoxamine; Humans; Hydrogen-Ion Concentration; Iron; Potentiometry; Pyridones; Transferrin | 1992 |
Iron chelation.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Pyridones; Thalassemia; Transfusion Reaction | 1991 |
Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice.
Topics: Animals; Deferiprone; Deferoxamine; Hydroxamic Acids; Iron; Isoniazid; Male; Mice; Mice, Inbred Strains; Pyridones; Pyridoxal; Tissue Distribution | 1991 |
Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Topics: Animals; Deferiprone; Deferoxamine; Iron; Iron Chelating Agents; Iron Radioisotopes; Macrophages; Mice; Mimosine; Pyridones; Pyrones | 1990 |
Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity.
Topics: Adenosine Diphosphate; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Collagen; Deferiprone; Deferoxamine; Epinephrine; Humans; Iron; Iron Chelating Agents; Lipoxygenase; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyridones; Thromboxane A2 | 1989 |
Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines.
Topics: Administration, Oral; Cell Cycle; Cell Survival; Deferiprone; Deferoxamine; Humans; Hydroxybenzoates; Neuroblastoma; Pyridines; Pyridones; Thiones; Tumor Cells, Cultured | 1989 |
The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Topics: Aluminum; Animals; Aorta; Arachidonic Acid; Arachidonic Acids; Ascorbic Acid; Calcimycin; Deferiprone; Deferoxamine; Epinephrine; Epoprostenol; Hydrogen Peroxide; Iron; Iron Chelating Agents; Male; Pyridones; Rats; Rats, Inbred Strains | 1988 |
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Topics: Animals; Deferiprone; Deferoxamine; Female; Ferritins; Iron; Iron Chelating Agents; Iron Radioisotopes; Liver; Male; Pyridones; Rats; Rats, Inbred Strains; Time Factors; Transferrin | 1987 |
Dose response studies using desferrioxamine and orally active chelators in a mouse model.
Topics: Administration, Oral; Animals; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Iron; Iron Chelating Agents; Male; Mice; Pyridones; Time Factors | 1986 |
Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.
Topics: Chelating Agents; Deferiprone; Deferoxamine; Dialysis; Ferritins; Iron; Ketones; Pyridones; Pyrones; Spectrophotometry | 1986 |
Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.
Topics: Administration, Oral; Animals; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Deferiprone; Deferoxamine; Dopamine; Female; Hydroxyindoleacetic Acid; Iron Chelating Agents; Male; Pyridones; Rats; Serotonin; Tryptophan Hydroxylase; Tyrosine; Tyrosine 3-Monooxygenase | 1993 |
Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells.
Topics: Biological Transport; Carcinoma, Hepatocellular; Cell Death; Deferiprone; Deferoxamine; Diffusion; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Iron Radioisotopes; Kinetics; Liver; Liver Neoplasms; Nitrilotriacetic Acid; Pyridones; Quaternary Ammonium Compounds; Transferrin; Tumor Cells, Cultured | 1995 |
Preliminary results of deferoxamine and L1 treatment of spinal cord ischemia.
Topics: Animals; Deferiprone; Deferoxamine; Dogs; Iron Chelating Agents; Ischemia; Pyridones; Reperfusion Injury; Spinal Cord | 1995 |
EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine.
Topics: Antioxidants; Cells, Cultured; Deferiprone; Deferoxamine; Electron Spin Resonance Spectroscopy; Iron; Iron Chelating Agents; Lipid Peroxidation; Liver; Nitrogen Oxides; Oligopeptides; Pigments, Biological; Pyridines; Pyridones; Spin Labels | 1995 |
Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.
Topics: Animals; Deferiprone; Deferoxamine; DNA; Electrophoresis, Polyacrylamide Gel; Immunoblotting; Iodine Radioisotopes; Iron Chelating Agents; Leishmania infantum; Leishmania major; Pyridones; Transferrin | 1995 |
Iron chelators induce apoptosis in proliferating cells.
Topics: Apoptosis; Cell Division; Cells, Cultured; Deferiprone; Deferoxamine; Electrophoresis, Agar Gel; Granulocytes; Humans; Iron Chelating Agents; Lymphocyte Activation; Lymphocytes; Pyridones; T-Lymphocytes; Tumor Cells, Cultured | 1995 |
Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
Topics: Aluminum; Blood Proteins; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Kinetics; Protein Binding; Pyridones; Reference Values; Spectrophotometry, Atomic; Temperature; Thermodynamics; Time Factors; Ultrafiltration | 1994 |
An orally active iron chelator.
Topics: Administration, Oral; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones | 1995 |
Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats.
Topics: Aluminum; Animals; Chelating Agents; Citrates; Citric Acid; Deferiprone; Deferoxamine; Female; Injections, Intraperitoneal; Pyridones; Rats; Rats, Sprague-Dawley; Succinates; Succinic Acid; Tissue Distribution; Uremia | 1994 |
The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.
Topics: Biological Transport; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Mannitol; Pyridones; Tumor Cells, Cultured | 1994 |
The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system.
Topics: Agranulocytosis; Bone Marrow; Cell Division; Cells, Cultured; Deferiprone; Deferoxamine; Humans; Middle Aged; Pyridones | 1994 |
[Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
Topics: Administration, Oral; Deferiprone; Deferoxamine; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones | 1994 |
Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Male; Pyridones; Thalassemia | 1993 |
Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders.
Topics: Animals; Bile; Deferiprone; Deferoxamine; Injections, Intravenous; Iron; Iron Chelating Agents; Male; Pyridones; Rats; Rats, Sprague-Dawley | 1994 |
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
Topics: Adolescent; Adult; Blood Glucose; Deferiprone; Deferoxamine; Diabetes Mellitus; Female; Glucose Tolerance Test; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Pyridones; Thalassemia; Zinc | 1994 |
Development of oral iron chelator L1.
Topics: Agranulocytosis; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Thalassemia | 1993 |
Future of oral iron chelator deferiprone (L1)
Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Mice; Pyridones | 1993 |
Misinformation about deferiprone (L1)
Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones | 1993 |
Effects of chelators on iron uptake and release by the brain in the rat.
Topics: 2,2'-Dipyridyl; Aging; Animals; Biological Transport; Bone and Bones; Brain; Deferiprone; Deferoxamine; Female; Iron; Iron Chelating Agents; Iron Radioisotopes; Isoniazid; Kidney; Liver; Male; Pentetic Acid; Pyridones; Pyridoxal; Rats; Rats, Wistar | 1994 |
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Child; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Female; Humans; Iron; Iron Chelating Agents; Pyridones | 1994 |
Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
Topics: 5'-Nucleotidase; Administration, Oral; Animals; beta-N-Acetylhexosaminidases; Cells, Cultured; Deferiprone; Deferoxamine; Heart; Iron; Iron Chelating Agents; Lysosomes; Myocardium; Pyridones; Rats; Sarcolemma; Sodium-Potassium-Exchanging ATPase; Sulfhydryl Compounds | 1994 |
Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro.
Topics: Bone Marrow Cells; Cell Division; Deferiprone; Deferoxamine; Hematopoiesis; Humans; In Vitro Techniques; Iron Chelating Agents; Pyridones; Thalassemia | 1994 |
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Topics: Animals; Deferiprone; Deferoxamine; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Pyridones; Rhizopus; Transferrin | 1994 |
Hydroxypyridinones and desferrioxamine inhibit macrophage-mediated LDL oxidation by iron but not by copper.
Topics: Animals; Copper; Copper Sulfate; Deferiprone; Deferoxamine; Ferrous Compounds; Humans; In Vitro Techniques; Iron Chelating Agents; Lipoproteins, LDL; Macrophages, Peritoneal; Mice; Pyridones | 1993 |
Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Topics: Aluminum; Binding, Competitive; Copper; Deferiprone; Deferoxamine; Iron Chelating Agents; Metals; Pyridones; Spectrophotometry | 1993 |
Action of reactive oxygen species and their antagonists on twitch tension of the rat phrenic nerve-diaphragm.
Topics: Analysis of Variance; Animals; Catalase; Deferiprone; Deferoxamine; Diaphragm; Free Radical Scavengers; Iron Chelating Agents; Male; Neuromuscular Junction; Phrenic Nerve; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxide Dismutase; Thiourea; Tiopronin; Vitamin E | 1995 |
The effectiveness of deferiprone in thalassemia.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Thalassemia | 1997 |
Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; beta-N-Acetylhexosaminidases; Cells, Cultured; Deferiprone; Deferoxamine; Doxorubicin; Female; Heart; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Mitochondria, Heart; Myocardium; Pyridones; Rats; Rats, Wistar | 1996 |
Counseling sexually active teenagers treated with potential human teratogens.
Topics: Adolescent; Adolescent Behavior; Anemia, Sickle Cell; beta-Thalassemia; Contraception Behavior; Counseling; Deferiprone; Deferoxamine; Female; Fertility; Humans; Iron Chelating Agents; Pregnancy; Pyridones; Sex Education; Sexual Behavior; Teratogens | 1997 |
EPR determination of low molecular weight iron content applied to whole rat hepatocytes.
Topics: Animals; Cells, Cultured; Deferiprone; Deferoxamine; Electron Spin Resonance Spectroscopy; Ethanol; Interferon-gamma; Iron; Iron Chelating Agents; Lipopolysaccharides; Liver; Oxidants; Oxidative Stress; Pyridones; Rats; Rats, Sprague-Dawley | 1997 |
Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Topics: Administration, Oral; Animals; Child, Preschool; Deferiprone; Deferoxamine; Drug Delivery Systems; Drug Screening Assays, Antitumor; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Liver; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Pyridones; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
Topics: Alkaline Phosphatase; Cell Division; Deferiprone; Deferoxamine; Iron; Iron Chelating Agents; Osteoblasts; Pyridones; Tumor Cells, Cultured | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Liver Cirrhosis; Pyridones | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones | 1998 |
Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells.
Topics: Animals; Animals, Newborn; Antioxidants; Ascorbic Acid; Cells, Cultured; Deferiprone; Deferoxamine; Heart; Intracellular Membranes; Iron; Iron Chelating Agents; Mitochondria, Heart; Myocardium; NAD; Pyridones; Rats; Succinate Dehydrogenase; Vitamin E | 1999 |
Bone density and metabolism in thalassaemia.
Topics: Absorptiometry, Photon; Adolescent; Age Determination by Skeleton; Amino Acids; beta-Thalassemia; Blood Transfusion; Body Height; Bone Density; Child; Collagen; Collagen Type I; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Osteoblasts; Osteocalcin; Osteoclasts; Peptide Fragments; Peptides; Procollagen; Pyridones | 1998 |
Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Topics: Aldehydes; beta-Thalassemia; Biomarkers; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Lipid Peroxidation; Pilot Projects; Pyridones; Transferrin | 1999 |
Aluminum speciation studies in biological fluids. Part 5. A quantitative investigation of A1(III) complex equilibria with desferrioxamine, 2,3-dihydroxybenzoic acid, Tiron, CP20 (L1), and CP94 under physiological conditions, and computer-aided assessment
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aluminum; Animals; Body Fluids; Chelating Agents; Computer Simulation; Deferiprone; Deferoxamine; Humans; Hydroxybenzoates; Indicators and Reagents; Inflammation; Iron Chelating Agents; Ligands; Pyridones; Rabbits; Rats; Reproducibility of Results | 1999 |
Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
Topics: Adolescent; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Treatment Outcome | 1999 |
Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
Topics: Adolescent; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Female; Humans; Iron Chelating Agents; Male; Pyridones; Students; Turkey | 1999 |
Chelation therapy in aluminum-loaded rats: influence of age.
Topics: Aging; Aluminum; Animals; Antidotes; Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Male; Pyridines; Pyridones; Rats; Rats, Sprague-Dawley; Tissue Distribution | 1999 |
Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
Topics: Anti-HIV Agents; Bleomycin; Cytotoxicity, Immunologic; Deferiprone; Deferoxamine; Didanosine; Drug Synergism; HIV Core Protein p24; HIV-1; Humans; Iron Chelating Agents; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Macrophages; Monocytes; Pyridones; Virus Replication | 2000 |
Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
Topics: beta-Thalassemia; Body Height; Bone Diseases; Deferiprone; Deferoxamine; Growth Disorders; Humans; Infant; Iron Chelating Agents; Knee; Male; Pyridones | 2000 |
Chelation of aluminium by combining DFO and L1 in rats.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Iron; Iron Chelating Agents; Pyridones; Rats; Rats, Wistar | 2000 |
Age-Related differences on aluminium mobilization by chelating agents in aluminium-loaded uraemic rats.
Topics: Administration, Oral; Aging; Aluminum; Aluminum Compounds; Animals; Anthelmintics; Chelating Agents; Deferiprone; Deferoxamine; Drug Therapy, Combination; Injections, Subcutaneous; Male; Nitrates; Pyridones; Rats; Rats, Sprague-Dawley; Uremia | 2000 |
Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Topics: Australia; beta-Thalassemia; Blood Transfusion; Chelating Agents; Chlorides; Comet Assay; Deferiprone; Deferoxamine; DNA Damage; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Hemosiderin; Humans; Lymphocytes; Male; Pyridones; Reference Values; Spleen | 2000 |
L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients.
Topics: Antioxidants; beta-Thalassemia; Deferiprone; Deferoxamine; Erythrocytes; Hemoglobins; Humans; Iron Chelating Agents; Leukocytes; Oxidation-Reduction; Oxygen; Pyridones | 2000 |
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Topics: Adolescent; Adult; Apoproteins; Calibration; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fluorescein; Humans; Iron; Iron Chelating Agents; Iron Overload; Kinetics; Microscopy, Fluorescence; Pyridones; Transferrin | 2001 |
Radiation sensitization of mammalian cells by metal chelators.
Topics: Animals; Cell Cycle; Chelating Agents; Colony-Forming Units Assay; Cricetinae; Cricetulus; Deferiprone; Deferoxamine; DNA Replication; Edetic Acid; Fibroblasts; Genes, p53; Humans; Iron Chelating Agents; Lung; Lung Neoplasms; Mimosine; Pyridones; Radiation-Sensitizing Agents; S Phase; Tumor Cells, Cultured | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles | 2001 |
Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Blood Transfusion; Cells, Cultured; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Iron; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Myocardium; Pyridones; Rats; Rats, Wistar | 2001 |
Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
Topics: Animals; Apoptosis; Deferiprone; Deferoxamine; Dietary Supplements; Drug Synergism; Enzyme Inhibitors; Ethylenediamines; Iron Chelating Agents; Male; Mice; Mice, Inbred BALB C; Pyridines; Pyridones; Thymus Gland; Type C Phospholipases; Zinc | 2001 |
The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
Topics: Animals; Catalase; Deferiprone; Deferoxamine; Glutathione; Glutathione Peroxidase; Iron Chelating Agents; Iron Overload; Iron, Dietary; Lipid Peroxides; Liver; Male; Mice; Pyridones | 2002 |
The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
Topics: Animals; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Gerbillinae; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pyridones | 2002 |
Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.
Topics: Apoptosis; Cell Division; Deferiprone; Deferoxamine; Female; G1 Phase; Growth Inhibitors; HeLa Cells; Humans; Iron Chelating Agents; Papillomaviridae; Papillomavirus Infections; Pyridones; Resting Phase, Cell Cycle; Tumor Cells, Cultured; Tumor Virus Infections; Uterine Cervical Neoplasms | 2002 |
Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.
Topics: 2,2'-Dipyridyl; Animals; Chelating Agents; Culture Media; Deferiprone; Deferoxamine; Iron Chelating Agents; Kinetics; Mice; Microbial Sensitivity Tests; Pyridones; Yersinia enterocolitica; Yersinia Infections | 2002 |
Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Myocardium; Pyridones | 2002 |
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
Topics: Administration, Oral; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Echocardiography; Female; Humans; Injections, Subcutaneous; Iron; Iron Chelating Agents; Male; Myocardium; Pyridones; Ventricular Function | 2002 |
Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
Topics: Adolescent; Adult; Antibody Formation; Autoantibodies; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Evaluation; Female; Histones; Humans; Immunoglobulin G; Iron Chelating Agents; Male; Pyridones | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: Administration, Oral; beta-Thalassemia; Deferiprone; Deferoxamine; Heart; Humans; Injections, Subcutaneous; Iron Chelating Agents; Linear Models; Liver; Pyridones | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: Animals; beta-Thalassemia; Deferiprone; Deferoxamine; Heart; Humans; Iron Chelating Agents; Liver; Pyridones | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Reproducibility of Results | 2003 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Half-Life; Humans; Iron; Iron Chelating Agents; Pyridones | 2003 |
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Topics: Animals; Deferiprone; Deferoxamine; Ferric Compounds; Hepatocytes; Iron; Iron Chelating Agents; Iron Radioisotopes; Kinetics; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tumor Cells, Cultured | 2003 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pyridones | 2003 |
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies | 2003 |
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
Topics: Aluminum; Animals; Bone Neoplasms; Calcitriol; Cattle; Chelating Agents; Culture Media; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Humans; Osteoblasts; Osteocalcin; Osteosarcoma; Pyridones; Secretory Rate; Serum Albumin, Bovine; Tumor Cells, Cultured | 2003 |
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Magnetics; Prospective Studies; Pyridones; Treatment Outcome | 2003 |
Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice.
Topics: Animals; Cell Division; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron, Dietary; Mice; Mice, Inbred BALB C; Mice, Nude; Pyridones; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2003 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2003 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Heart Failure; Hepatitis C, Chronic; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Osteoporosis; Pyridones; Splenectomy; Transfusion Reaction; Tricuspid Valve Insufficiency | 2004 |
Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferiprone; Deferoxamine; Humans; Immunophenotyping; Pyridones | 2003 |
Iron: a target for the management of Kaposi's sarcoma?
Topics: Africa; Deferiprone; Deferoxamine; Female; Herpesvirus 8, Human; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Sarcoma, Kaposi; Topography, Medical | 2004 |
Independent clinical trials.
Topics: Anemia, Sickle Cell; Deferiprone; Deferoxamine; Drug Industry; Financial Support; Humans; Multicenter Studies as Topic; Pyridones; Randomized Controlled Trials as Topic; Research Support as Topic; Thalassemia | 2004 |
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.
Topics: Adult; Ceruloplasmin; Chelation Therapy; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Mutation, Missense; Pedigree; Pyridones | 2004 |
Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Synergism; Drug Therapy, Combination; Heart Failure; Humans; Iron; Iron Chelating Agents; Male; Pyridones | 2005 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
Topics: Animals; Benzoates; Catalysis; Cell Line; Cell Survival; Cells; Cytosol; Deferasirox; Deferiprone; Deferoxamine; Endosomes; Humans; Iron; Iron Chelating Agents; Mice; Microscopy, Fluorescence; Mitochondria; Pyridones; Time Factors; Triazoles | 2005 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosiderosis; Humans; Liver Failure; Male; Pyridones | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones | 2005 |
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Heart Diseases; Humans; Iron Chelating Agents; Italy; Male; Pyridones | 2006 |
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Pyridones | 2006 |
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thiazoles; Transfusion Reaction | 2006 |
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
Topics: Adolescent; Anemia, Sideroblastic; Biomarkers; Bone Marrow Transplantation; Chelation Therapy; Combined Modality Therapy; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Phlebotomy; Pyridones; Retrospective Studies | 2006 |
Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosiderosis; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome | 2006 |
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Child; Combined Modality Therapy; Deferiprone; Deferoxamine; Drug Evaluation; Female; Hepatitis B; Hepatitis C; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Liver Cirrhosis; Male; Pyridones; Retrospective Studies; Severity of Illness Index; Transfusion Reaction | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Modality Therapy; Deferiprone; Deferoxamine; False Negative Reactions; Female; Ferritins; Heart Failure; Hemosiderosis; Humans; Infusions, Intravenous; Infusions, Parenteral; Iron Chelating Agents; Longitudinal Studies; Magnetic Resonance Imaging; Pyridones; Risk; Subcutaneous Tissue; Thalassemia; Transfusion Reaction | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studies; Combined Modality Therapy; Deferiprone; Deferoxamine; Drug Evaluation; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Hemosiderosis; Humans; Infant; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Stroke Volume; Transfusion Reaction | 2006 |
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality Therapy; Comorbidity; Deferiprone; Deferoxamine; Female; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Oxidative Stress; Polymorphism, Genetic; Pyridones; Stroke Volume; Transfusion Reaction | 2006 |
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Data Collection; Deferiprone; Deferoxamine; Drug Utilization; Female; Genetic Carrier Screening; Genetic Counseling; Genetic Testing; Humans; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Marriage; National Health Programs; Public Opinion; Pyridones; Sri Lanka; Thalassemia; Transfusion Reaction | 2006 |
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalassemia; Chelation Therapy; Child; Combined Modality Therapy; Creativity; Deferiprone; Deferoxamine; Female; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Male; Parents; Patient Acceptance of Health Care; Patients; Pilot Projects; Pyridones; Quality of Life; Self Concept; Taiwan; Transfusion Reaction | 2006 |
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalassemia; Chelation Therapy; Child; Combined Modality Therapy; Deferiprone; Deferoxamine; Female; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Male; Parent-Child Relations; Parents; Patient Acceptance of Health Care; Patients; Pilot Projects; Pyridones; Quality of Life; Socioeconomic Factors; Stress, Psychological; Taiwan; Transfusion Reaction | 2006 |
Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Analysis of Variance; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Insulin; Iron Chelating Agents; Iron Overload; Male; Pyridones; Treatment Outcome | 2006 |
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Ascorbic Acid; Deferiprone; Deferoxamine; Deoxyguanosine; Glutathione; Heart; Heart Diseases; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Pyridones; Rats; Thiobarbituric Acid Reactive Substances | 2006 |
Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
Topics: Animals; Chelating Agents; Deferiprone; Deferoxamine; Iron; Male; Pyridones; Rats; Rats, Wistar; Siderophores; Thallium | 2007 |
Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Iron Chelating Agents; Male; Pyridones; Retrospective Studies | 2007 |
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.
Topics: Cyprus; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Risk Factors; Survival Rate; Thalassemia | 2006 |
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Topics: Adult; Amino Acid Substitution; Antimicrobial Cationic Peptides; Atrial Fibrillation; Chelation Therapy; Deferiprone; Deferoxamine; DNA Mutational Analysis; Drug Therapy, Combination; Heart Failure; Hemochromatosis; Hepcidins; Humans; Infertility, Male; Iron Chelating Agents; Male; Mutation, Missense; Pedigree; Point Mutation; Pyridones; Remission Induction | 2007 |
Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
Topics: Adult; beta-Thalassemia; Cardiomyopathy, Dilated; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Recovery of Function | 2007 |
Physical growth patterns and dental caries in thalassemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Deferoxamine; Dental Caries; Female; Ferritins; Growth Disorders; Hemoglobins; Humans; Infant; Iron Chelating Agents; Male; Prevalence; Pyridones; Siderophores; Thalassemia | 2006 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies; Chelation Therapy; Cytokines; Deferiprone; Deferoxamine; Female; Humans; Intercellular Signaling Peptides and Proteins; Iron Chelating Agents; Male; Osteocalcin; Osteoporosis; Parathyroid Hormone; Pyridones; Risk Factors; Siderophores; Vitamin D | 2006 |
Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
Topics: Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Pyridones; Treatment Outcome | 2007 |
Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Topics: Chromatography, High Pressure Liquid; Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Spectrophotometry, Ultraviolet; Thalassemia; Transferrin | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferiprone; Deferoxamine; Erythrocytes; Female; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Oxidative Stress; Pyridones | 2007 |
Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Electrocardiography; Female; Heart Diseases; Humans; Pyridones; Siderophores | 2007 |
comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Ferritins; Heart Ventricles; Humans; Iron; Liver; Longitudinal Studies; Magnetic Resonance Imaging; Male; Monitoring, Physiologic; Myocardium; Organ Size; Pyridones; Radiography; Siderophores; Time Factors | 2007 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles | 2008 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Prescriptions; Erythrocyte Transfusion; Female; Ferritins; Hepatitis B; Hepatitis C; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Male; Middle Aged; Outcome Assessment, Health Care; Outpatient Clinics, Hospital; Patient Compliance; Pyridones; Retrospective Studies; Siderophores; Thalassemia; Time Factors | 2008 |
A new lactoferrin- and iron-dependent lysosomal death pathway is induced by benzo[a]pyrene in hepatic epithelial cells.
Topics: Acridine Orange; Animals; Apoptosis; Benzo(a)pyrene; Carcinogens; Caspase 3; Cell Line; Cell Size; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Epithelial Cells; Iron; Iron Chelating Agents; Lactoferrin; Liver; Lysosomes; Microscopy, Electron; Models, Biological; Oxidative Stress; Pyridones; Rats; RNA, Small Interfering; Transfection | 2008 |
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Microscopy, Electron, Transmission; Middle Aged; Muscle Cells; Myocardium; Pyridones; Thalassemia | 2008 |
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones | 2008 |
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Topics: Adolescent; Adult; Autoantibodies; B-Lymphocytes; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Evoked Potentials; Ferritins; Humans; Immune System; Immunologic Factors; Iron Chelating Agents; Iron Overload; Pyridones; T-Lymphocytes | 2008 |
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Topics: Adult; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pyridones; Thalassemia | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles | 2008 |
Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Patient Compliance; Pyridones; Siderophores | 2008 |
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Gerbillinae; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Siderophores; Tissue Distribution; Triazoles | 2008 |
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Quality of Life; Young Adult | 2008 |
Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
Topics: Animals; Bismuth; Body Weight; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Eating; Iron; Iron Chelating Agents; Kidney; Male; Pyridones; Rats; Rats, Wistar; Siderophores | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure | 2008 |
Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier.
Topics: Adult; Blood Transfusion; Deferiprone; Deferoxamine; Hepatitis B; Hepatitis B virus; Humans; Iron Chelating Agents; Male; Pyridones; Siderophores; Thalassemia; Virus Activation | 2009 |
Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Microbial Sensitivity Tests; Pyridones; Staphylococcus; Staphylococcus aureus; Transferrin | 2009 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus | 2009 |
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Liver; Logistic Models; Magnetic Resonance Imaging; Male; Myocardium; Pyridones; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.
Topics: Adult; beta-Thalassemia; Biomarkers; Circadian Rhythm; Deferiprone; Deferoxamine; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Pyridones | 2009 |
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Testing; Humans; Iron Chelating Agents; Iron Overload; Pregnancy; Prenatal Diagnosis; Pyridones; Quality of Life; Siderophores; Thalassemia | 2009 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles | 2009 |
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxa
Topics: Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Diagnosis, Differential; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Siderophores; Thalassemia; Young Adult | 2009 |
A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pyridones; Siderophores; Young Adult | 2009 |
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Topics: Blood Transfusion; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2009 |
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Multivariate Analysis; Pyridones; Siderophores; Survival Analysis; Time Factors; Young Adult | 2009 |
Early cardiac iron overload in children with transfusion-dependent anemias.
Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Pyridones; Risk Factors | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles | 2010 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult | 2010 |
Combining two orally active iron chelators for thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Siderophores; Thalassemia; Treatment Outcome; Young Adult | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pyridones | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2010 |
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Pyridones; Time Factors | 2010 |
Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Male; Prospective Studies; Pyridones; Ventricular Dysfunction, Left | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2010 |
Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
Topics: Binding Sites; Chromatography, Gel; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Metalloproteins; Pyridones; Serum Albumin; Spectrophotometry, Atomic; Zinc | 2010 |
More pieces to the iron chelation puzzle.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Transfusion Reaction | 2010 |
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Iron Overload; Kinetics; Male; Pyridones; Siderophores; Thalassemia; Transferrin; Transfusion Reaction | 2010 |
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Prospective Studies; Pyridones; Survival Rate | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles | 2010 |
Deferiprone.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Transfusion Reaction | 2010 |
Combined iron chelation therapy.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult | 2011 |
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Pyridones; Recombinant Proteins; Retrospective Studies; Siderophores | 2010 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles | 2010 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles | 2011 |
Quercetin-iron chelates are transported via glucose transporters.
Topics: Animals; Cytochalasin B; Deferiprone; Deferoxamine; Dogs; Glucose Transport Proteins, Facilitative; Iron Chelating Agents; Pyridones; Quercetin; Signal Transduction; Spectrometry, Fluorescence | 2011 |
In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
Topics: Antimalarials; Benzoates; Chloroquine; Deferasirox; Deferiprone; Deferoxamine; Glutathione; Hemeproteins; Hemin; Hydrogen Peroxide; Inhibitory Concentration 50; Iron Chelating Agents; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid | 2011 |
Iron chelation in thalassemia: time to reconsider our comfort zones.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles | 2011 |
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles | 2011 |
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; Greece; Humans; Iron Chelating Agents; Iron Overload; Italy; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Siderophores; Stroke Volume; Time Factors; Transfusion Reaction; Treatment Outcome; Ventricular Function, Left; Ventricular Function, Right; Young Adult | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Chi-Square Distribution; Deferiprone; Deferoxamine; Drug Therapy, Combination; Echocardiography, Doppler; Female; Hemosiderosis; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Male; Pyridones; Randomized Controlled Trials as Topic; Recovery of Function; Retrospective Studies; Severity of Illness Index; Siderophores; Stroke Volume; Therapeutics; Time Factors; Ventricular Dysfunction, Right; Ventricular Function, Right | 2012 |
Health-related quality of life in Thai thalassemic children treated with iron chelation.
Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles | 2011 |
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult | 2012 |
Antibacterial activities of iron chelators against common nosocomial pathogens.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Deferiprone; Deferoxamine; Iron Chelating Agents; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pyridones; Staphylococcus aureus | 2012 |
Iron(III)-doped, silica nanoshells: a biodegradable form of silica.
Topics: Animals; Biocompatible Materials; Cattle; Deferiprone; Deferoxamine; Edetic Acid; Ferric Compounds; Humans; Iron Chelating Agents; Nanoshells; Pyridones; Serum; Silicon Dioxide; Transferrin | 2012 |
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Topics: Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron Overload; Metals; Poisoning; Pyridones; Risk Assessment; Thalassemia; Treatment Outcome; United States | 2013 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Body Burden; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pancrelipase; Pyridones; Spleen; Young Adult | 2013 |
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult | 2013 |
Iron-chelation therapy with oral chelators in patients with thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult | 2013 |
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Italy; Liver; Magnetic Resonance Imaging, Cine; Male; Myocardium; Predictive Value of Tests; Prospective Studies; Pyridones; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Function, Right; Young Adult | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult | 2013 |
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left; Young Adult | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles | 2013 |
Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Audiometry, Pure-Tone; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferiprone; Deferoxamine; Evoked Potentials, Auditory, Brain Stem; Female; Hearing Loss; Humans; Male; Pyridones; Vestibule, Labyrinth; Young Adult | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
FT-Raman study of deferoxamine and deferiprone exhibits potent amelioration of structural changes in the liver tissues of mice due to aluminum exposure.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Liver; Male; Mice; Pyridones; Spectroscopy, Fourier Transform Infrared | 2014 |
FTIR study of protective action of deferoxamine and deferiprone on the kidney tissues of aluminum loaded mice.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Kidney; Male; Mice; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared | 2014 |
Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Chi-Square Distribution; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Health Knowledge, Attitudes, Practice; Humans; Iron Chelating Agents; Patient Compliance; Public Opinion; Pyridones; Surveys and Questionnaires; Young Adult | 2014 |
Mefloquine in combination with hemin causes severe damage to adult Schistosoma japonicum in vitro.
Topics: 2,2'-Dipyridyl; Animals; Anthelmintics; Ascorbic Acid; Cysteine; Deferiprone; Deferoxamine; Drug Synergism; Drug Therapy, Combination; Ferric Compounds; Ferrous Compounds; Glutathione; Hemin; Inhibitory Concentration 50; Iron Chelating Agents; Mefloquine; Protoporphyrins; Pyridones; Schistosoma japonicum | 2014 |
In vitro screening of Fe2+-chelating effect by a Fenton's reaction-luminol chemiluminescence system.
Topics: Deferiprone; Deferoxamine; Edetic Acid; Ferrous Compounds; Iron Chelating Agents; Luminescence; Luminol; Molecular Structure; Phenanthrolines; Pyridones | 2014 |
Laboratory investigation of platelet function in patients with thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult | 2014 |
Studies the alterations of biochemical and mineral contents in bone tissue of mus musculus due to aluminum toxicity and the protective action of desferrioxamine and deferiprone by FTIR, ICP-OES, SEM and XRD techniques.
Topics: Aluminum; Animals; Bone and Bones; Deferiprone; Deferoxamine; Iron Chelating Agents; Male; Mice; Microscopy, Electron, Scanning; Minerals; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2014 |
Protective effects of desferrioxamine and deferiprone on the spleen tissue of aluminum intoxicated mice: A Fourier transform infrared spectroscopy study.
Topics: Aluminum; Animals; Deferiprone; Deferoxamine; Male; Mice; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared; Spleen | 2014 |
Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Heterozygote; Iron; Iron Chelating Agents; Iron-Dextran Complex; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Pyridones; Tissue Distribution | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult | 2015 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; Iron Metabolism Disorders; Iron Overload; Male; Neurodegenerative Diseases; Pyridones; Siderophores | 2015 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Hemangioendothelioma; Hemosiderosis; Humans; Infant; Iron; Iron Chelating Agents; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Myocardium; Pyridones; Severity of Illness Index; Survival Analysis; Transfusion Reaction | 2015 |
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Topics: Benzoates; Cell Line; Deferasirox; Deferiprone; Deferoxamine; Drug Synergism; Humans; Intracellular Space; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2015 |
A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.
Topics: beta-Thalassemia; Copper; Deferiprone; Deferoxamine; Humans; Ions; Iron Chelating Agents; Metals; Pyridones; Serum Albumin; Zinc | 2015 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles | 2015 |
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzoates; Biofilms; Chlorides; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Plankton; Pyridones; Spores, Fungal; Tetrazolium Salts; Triazoles | 2015 |
Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Topics: Adult; Anemia, Aplastic; Deferiprone; Deferoxamine; Echocardiography; Hemochromatosis; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Male; Myocardial Contraction; Pyridones; Transfusion Reaction; Ventricular Dysfunction, Left | 2015 |
Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice.
Topics: Animals; Antidotes; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Dextrans; Female; Fibrosis; Iron Chelating Agents; Iron Overload; Lung; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Pyridones; Respiratory Mucosa | 2015 |
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,2'-Dipyridyl; Animals; Antioxidants; Deferiprone; Deferoxamine; Dopaminergic Neurons; Female; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Hydroxyquinolines; Iron Chelating Agents; Lipid Peroxidation; Male; Mesencephalon; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Fibers; Neurites; Neuroprotective Agents; Primary Cell Culture; Pyridones; Rats; Rats, Sprague-Dawley; Synaptophysin; Tyrosine 3-Monooxygenase | 2015 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult | 2015 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles | 2016 |
The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population.
Topics: Adult; Ambulatory Care Facilities; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Italy; Male; Prognosis; Pyridones; Registries; Surveys and Questionnaires; Thalassemia | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
Therapeutic deferoxamine and deferiprone monitoring in β-thalassemia patients' plasma by field-amplified sample injection and sweeping in capillary electrophoresis.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Electrophoresis, Capillary; Humans; Limit of Detection; Pyridones; Reproducibility of Results | 2016 |
Iron distribution and histopathological study of the effects of deferoxamine and deferiprone in the kidneys of iron overloaded β-thalassemic mice.
Topics: Animals; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Iron; Iron Chelating Agents; Kidney; Male; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Pyridones; Tissue Distribution | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromatosis Protein; Humans; Iron Chelating Agents; Iron Overload; Liver Diseases; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Pyridones; Severity of Illness Index; Stroke Volume; Transferrin; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles | 2017 |
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles | 2017 |
Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myocardium; Pyridones | 2017 |
Thalassemia: Yesterday, Today, Tomorrow.
Topics: Attitude of Health Personnel; Attitude to Health; Chelation Therapy; Cyprus; Deferiprone; Deferoxamine; Disease Management; Drug Approval; Female; History, 20th Century; History, 21st Century; Humans; Iron Chelating Agents; Life Style; Parent-Child Relations; Power, Psychological; Pyridones; Self Care; Social Stigma; Social Support; Splenectomy; Thalassemia; United States; United States Food and Drug Administration | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2018 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cardiotoxicity; Deferiprone; Deferoxamine; Deoxyguanosine; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Heart; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Nanotubes; NF-E2-Related Factor 2; Plant Extracts; Pyridones; Rats, Wistar; Tea; Thiobarbituric Acid Reactive Substances | 2018 |
Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Topics: Adolescent; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Female; Ferritins; Glucose Intolerance; Homeostasis; Humans; Infant; Insulin Resistance; Iron Chelating Agents; Iron Overload; Male; Prospective Studies; Pyridones; Young Adult | 2018 |
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Cross-Sectional Studies; Deferiprone; Deferoxamine; Female; Glycation End Products, Advanced; Humans; Iran; Iron Overload; Male; Oxidative Stress; Pyridones; Scavenger Receptors, Class E; Transfusion Reaction; Young Adult | 2018 |
The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies.
Topics: Bacteria; Catalysis; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Ferric Compounds; Humans; Hydroxamic Acids; Ion Transport; Iron; Iron Chelating Agents; Iron Overload; Kinetics; Ligands; Pyridones | 2018 |
Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles
Topics: Animals; Antifungal Agents; Azoles; Candida; Candida albicans; Deferiprone; Deferoxamine; Disease Models, Animal; Drug Resistance, Fungal; Drug Synergism; Female; Mice; Vaginitis | 2018 |
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Topics: Adult; Cardiomyopathies; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Extracorporeal Membrane Oxygenation; Female; Hemochromatosis; Humans; Iron Chelating Agents; Shock, Cardiogenic | 2018 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Prospective Studies; Treatment Outcome | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Overload; Myelodysplastic Syndromes; Transfusion Reaction | 2018 |
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.
Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Female; Fibrosis; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging, Cine; Male; Myocardium; Predictive Value of Tests; Prospective Studies; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling | 2020 |
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Transfusion Reaction; Treatment Outcome; Young Adult | 2020 |
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Iron Overload; Male; Quality of Life; Retrospective Studies; Thalassemia; Transfusion Reaction; Treatment Outcome; Ventricular Function, Left | 2020 |
HIF-1α Stimulators Function Equally to Leading Hair Loss Agents in Enhancing Dermal Papilla Growth.
Topics: Alopecia; Cells, Cultured; Deferiprone; Deferoxamine; Dermis; Hair Follicle; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Minoxidil; Siderophores; Spheroids, Cellular; Vasodilator Agents | 2020 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc | 2021 |
Characterisation of individual ferritin response in patients receiving chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2022 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Oxidopamine; PC12 Cells; Rats | 2022 |
New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis.
Topics: Amines; Animals; Deferiprone; Deferoxamine; Dextrans; Ferroptosis; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Mice; Nitrogen; Pyridones | 2022 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles | 2023 |
Successful chelation in beta-thalassemia major in the 21st century.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones | 2023 |